<DOC>
	<DOCNO>NCT00784446</DOCNO>
	<brief_summary>Assessment safety toxicity , definition dose limit toxicity ( DLT ) combination therapy consist Capecitabine , Oxaliplatin , Bevacizumab Imatinib .</brief_summary>
	<brief_title>First-line Therapy Stage IV Colorectal Cancer</brief_title>
	<detailed_description>The monoclonal anti-VEGF antibody bevacizumab approve treatment stage IV colorectal cancer . The tyrosine kinase inhibitor imatinib mesylate show efficiently target PDGF-signalling . Blocking PDGFR-signalling lead disruption pericytes endothelium revers maturation status thereby enhance sensitivity anti-VEGF therapy.This background form rationale combine therapeutic PDGF VEGF inhibition . Since bevacizumab show best activity use combination chemotherapy , capecitabine oxaliplatin include protocol . Patients stage IV colorectal cancer prior chemotherapy enter study . Patients receive oral imatinib day day 1-21 . Oral Capecitabine give day 1-14 bid , Oxaliplatin Bevacizumab give day 1 . Courses repeat every 22 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically proven inoperable colorectal cancer Adult patient &gt; = 18 year age ECOG &lt; 2 Preceding chemo immunotherapy exception adjuvant neoadjuvant treatment nonmetastatic disease end ≥ 6 month prior study inclusion . Progression within 6 month end adjuvant therapy must exclude . Other malignancy exception basal cell carcinoma successfully treat carcinoma situ cervix uterus . No history severe comorbidities , i. e. uncontrolled hypertension , GIbleeding , congestive heartfailure NYHA class IIIV , symptomatic coronary heart disease , myocardial infarction within 1 year prior study inclusion , serious cardiac arrhythmia require medication , Grade II great peripheral vascular disease severe uncontrolled comorbidities No history stroke CNSdiseases ( tumor , seizure , transient ischemic attack etc . ) ≥ Grade II peripheral artery vascular occlusive disease Preexisting neuropathy ≥ Grade 1 Interstitial pneumonia lung fibrosis Serious , nonhealing wound , ulcer , bone fracture Preceding irradiation indicator lesion except document progressive disease irradiation termination irradiation ≥ 4 week study inclusion Thromboembolic bleeding event within last 6 month Need therapeutic anticoagulation ( heparin , cumarin ) Use ASS &gt; 325 mg/die NSAR Proteinuria &gt; 1+ ( stix ) long urine protein &gt; 1g/24h</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>AIO</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>0205</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Imatinib</keyword>
</DOC>